source
- BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trialBioNTech reported results of its phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan (t-pam), an HER2-directed antibody-drug conjugate, in patients with HR-positive, HER2-low metastati…
- Australian clinical trials attract more U.S. sponsors amid regulatory uncertaintyCROs are reporting faster startup timelines, predictable regulation, and tax incentives as reasons for increasing interest in conducting clinical trials in Australia. State-level incentives in Que…